3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Neoplasms
13
Venous Thromboembolism
11
Venous Thrombosis
4
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Thrombosis
2
Pulmonary Embolism
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
1
Pancreatic Neoplasms
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Interventions
Dalteparin
4
Saline Solution
3
Gemcitabine
3
Enoxaparin
3
Warfarin
2
Tinzaparin
2
Heparin, Low-Molecular-Weight
2
Fondaparinux
2
Aspirin
2
130-nm albumin-bound paclitaxel
2
palbociclib
1
isoquercitrin
1
enoxaparin sodium
1
edoxaban
1
apixaban
1
alvocidib
1
Tranexamic Acid
1
Sodium Chloride
1
Sodium Bicarbonate
1
Rivaroxaban
1
Pentetic Acid
1
PEGPH20
1
Nadroparin
1
Minocycline
1
Ketoconazole
1
Heparin
1
Fluorodeoxyglucose F18
1
Fluoridation
1
Estramustine
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thromboembolism
×
Rivaroxaban
×
Clear all
NCT06065592
2023-10-06
CAT_PB
Lebanese University
Phase 1
Unknown
500 enrolled